MaxWell Biosystems Completes CHF 4 million Series A Financing Round to further industrialize and scale-up

16.12.2020 09:14, Jonatan Masseus

MaxWell Biosystems, a spin-off from ETH Zürich, develops and commercializes cell imaging systems that empower scientists in pharma and academia to reveal the function of neuronal networks in a dish. The Series A round was closed together with Sensirion Holding AG and other existing shareholders and business angels.

MaxWell Biosystems, a spin-off from ETH Zürich, develops and commercializes cell imaging systems that empower scientists in pharma and academia to reveal the function of neuronal networks in a dish. With these systems, users can accelerate the development of drugs targeting the brain and advance the understanding of the brain’s function. At the core of MaxWell Biosystems’ technology is a custom-designed microsensor, a high-density microelectrode array (HD-MEAs), with thousands of tiny electrodes simultaneously sensing the small electrical signals of neuronal cells.

The financing round A was closed together with Sensirion Holding AG and other existing shareholders and business angels. The funding will be allocated to further industrialize and scaleup the production of their consumables so called multiwell high-density microelectrode array (HD-MEA) plates. Such scale-up will enable the customers of MaxWell Biosystems in the pharmaceutical industry to run functional drug screenings at a higher throughput and ultimately contribute to accelerating the development of drugs targeting the brain.

MaxWell Biosystems has been supported by Venture Kick, Venture Leaders Life Sciences, and TOP100.